Paul Conyngham has turned his viral ChatGPT-designed dog cancer vaccine story into a Y Combinator-backed startup called Gamgee, which launched on Aug 12, 2026 selling personalized mRNA cancer vaccines for dogs. The pitch centers on a single documented case — Conyngham's Staffordshire bull terrier-Shar Pei mix Rosie — where the company claims a roughly 75% tumor reduction. Gamgee promises veterinarians a finished vaccine in about 4 weeks, with less than 20 minutes of chair time per case and no new clinical workflows.
Conyngham announced Gamgee on X, framing the Rosie case as the founding proof point. He credits ChatGPT and computational genomics with the vaccine design, and notes on the company's website that he himself is not a biologist. Prices are not disclosed on the Gamgee site.
“I used chatgpt + computational genomics to design a personalised mRNA cancer vaccine for her tumour. Several of her tumours shrank.”— Paul Conyngham, Founder of Gamgee
The company is running its first clinical trials in Australia in collaboration with the University of Queensland and institutes at the University of New South Wales. A global waitlist is open, and the site invites veterinarians, funders, and study partners to submit cases and inquiries.
Key facts
- 01Gamgee launched on Aug 12, 2026 with Y Combinator backing to sell personalized mRNA cancer vaccines for dogs.
- 02The company cites a 75% tumor reduction in its first documented case as its headline efficacy claim.
- 03Gamgee promises a finished vaccine in about 4 weeks and under 20 minutes of veterinarian time per case.
- 04Founder Paul Conyngham states on the site that he is 'not a biologist' and used ChatGPT and Grok to design the original vaccine.
- 05The startup is running clinical trials in Australia with the University of Queensland and University of New South Wales, and has a global waitlist.
Gamgee's ambitions do not stop at dogs. The company's website states it intends to apply the same AI-plus-genetics pipeline to a range of species and diseases, including humans. The launch materials include an AI-generated anime video and a slideshow of dogs with listed ages and cancer diagnoses.
The scientific record behind the founding case is thinner than the marketing suggests. As reported earlier this year by The Verge's Robert Hart, Rosie received the mRNA vaccine alongside another therapy, which makes it impossible to attribute her improvement to the vaccine alone. Researchers quoted in that earlier reporting said the AI-designed-my-dog's-vaccine framing gave the tools too much credit and understated the human expertise involved.
“accepting cases globally”— Paul Conyngham, Founder of Gamgee
Gamgee's own site carries a caveat that the 4-week turnaround and 75% tumor reduction figure are derived from a single case and may vary. That is a narrow evidentiary base on which to build a global veterinary oncology product, let alone a future human therapeutics business. mRNA cancer vaccines are an active area of legitimate research at pharma companies including Moderna and BioNTech, but those programs run through multi-year controlled trials, not case reports and waitlists.
The Y Combinator imprimatur will help Gamgee recruit vets, cases, and follow-on capital, and the veterinary market has looser regulatory constraints than human oncology — which is why several AI-driven biotech founders have started there. A cancer diagnosis in a pet dog is often a death sentence within months, and owners are frequently willing to try unproven interventions when standard-of-care options are exhausted. That creates a real market, and also a real risk of over-claiming.
What Gamgee has not disclosed is the size of any completed cohort beyond the founding case, the design of its planned Australian trials, or the pricing model that veterinarians and pet owners will see. The company says it is accepting cases globally through its waitlist, which is an unusually aggressive posture for a therapy with one published anecdote behind it.
The gap between Gamgee's headline claim and its evidence base is the story here. A 75% tumor reduction in one dog, delivered alongside a second therapy, is not a validated efficacy result — it is a hypothesis-generating anecdote. Anyone evaluating the company, whether as a customer, an investor, or a research partner, should ask for the cohort data before the anime video.
Gamgee is a clean example of a pattern that will repeat across AI-driven biotech: a founder with a compelling personal story, a plausible use of large models in the design pipeline, an incubator stamp, and a very small evidence base scaled quickly into a commercial pitch. Some of these companies will produce real medicine. Some will not. The market — and Rosie's fellow patients — will find out which is which the hard way, one case at a time.
Working on something we should cover, or seeing a story we missed? Send leads, documents, or feedback to hello@aichatdaily.com. For sensitive tips, see our secure tips page for Signal and PGP options.
Spotted an error? Email hello@aichatdaily.com with the URL and the issue, or read our full corrections policy.
